EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 68 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2015. The put-call ratio across all filers is - and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $499,000 | +43.4% | 6,600 | 0.0% | 0.01% | +25.0% |
| Q1 2018 | $348,000 | -1.4% | 6,600 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $353,000 | -10.4% | 6,600 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $394,000 | -24.4% | 6,600 | 0.0% | 0.00% | -33.3% |
| Q2 2017 | $521,000 | -53.6% | 6,600 | -56.4% | 0.01% | -73.9% |
| Q3 2015 | $1,122,000 | -56.8% | 15,150 | -52.8% | 0.02% | -54.9% |
| Q2 2015 | $2,597,000 | +94.0% | 32,118 | +0.5% | 0.05% | +82.1% |
| Q1 2015 | $1,339,000 | +170.0% | 31,968 | 0.0% | 0.03% | +154.5% |
| Q4 2014 | $496,000 | +130.7% | 31,968 | +88.4% | 0.01% | +120.0% |
| Q3 2014 | $215,000 | – | 16,968 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |